anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a sort of antivirus compound Chinese medicine, whose raw material includes: forsythia, arctium fruit, honeysuckle, belamcanda rhizome, pull ball and phragmites communis trin. The prescription of the invention is base on the ancient prescription of YINQIAOMABOSAN, and this medicine is made using the modern technological process. It can be prepared to any acceptable dosage form which is acceptable in pharmacy. The present invention also relates to the making method and new usage of this medicine. The beneficial effect of this medicine includes: Proved by experiment, the medicine of the invention have a prominent antivirus action. It has an evident antivirus effect of respiratory tract which is proved by a serious of experiments in vivo (mouse) and external experiments (cell), and it is close to the experiment results of the Shuanghuanglian oral liquid and ribavirin test; indicated by the external experiment of restraining the virus of atypical pneumonia, the restrain effect to the coronaviruses 04 in the cell V E R O   E6 is weaker than the ganciclovir, and it is only one thirty-second of the contrast medicine. Because it has heat-clearing and antitoxic effect, anti-inflammatory action, antibacterial effect and the like pharmacological effect, it has an auxiliary effect for treating the atypical pneumonia.
1. The baseline tests (sleeping tendency assessment, clinical symptom and cognitive assessments, clinical laboratory tests, genotyping, exploratory biomarker tests, etc.) are conducted to the schizophrenia patients before initiation of the clozapine dosing.
2. On day 15 and 57, the changes from baseline clinical symptom and cognitive function are assessed after clozapine treatment. Also, the occurrence of adverse drug reactions are evaluated. In addition, blood sample collections are performed for the assessment of clozapine and its metabolite levels.
Glaucoma is a disease that leads to optic nerve damage and irreversible loss of the visual field. Gonioscopy-assisted transluminal trabeculotomy (GATT) is a minimally invasive glaucoma surgery technique, where the surgeon opens the trabecular network and Schlemm's canal to improve the outflow of the aqueous humor. This method has shown efficacy in reducing intraocular pressure in patients with primary and secondary glaucoma. GATT has gained popularity due to its minimally invasive nature, compatibility with cataract surgery and relatively low cost. Despite its advantages, the procedure can be associated with many complications such as hyphema, intraocular pressure spikes and corneal edema. In rare cases, it can lead to Descemet's membrane detachment or cystoid macular edema. The success of GATT procedure mostly depends on the surgeon's skill and experience, but also on the patient's risk factors, including age and preoperative intraocular pressure levels. Further studies are required to understand long outcomes and identify the patients, who may be at higher risk of complications.
In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex with the Transcranial Direct Current Stimulation. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp. The device will deliver a charge of 2mA for 1 minute, after that the device will be automatically turned off for 29 minutes.
OBJECTIVES: Contrast-enhanced ultrasound (CEUS) is increasingly utilized for the noninvasive assessment of renal cystic lesions, using the Bosniak grading system. Bosniak 3-4 lesions require surgical referral, which allows correlation with the histopathological outcome.
METHODS: In this single-center, retrospective study we evaluated renal CEUS exams conducted with SonoVue® with a diagnosis of a Bosniak 3 or 4 lesion between 2019 and 2022. A total of 49 patients and 50 lesions met the inclusion criteria, 31 lesions had available histopathological results. Patient demographics, cyst morphology, and dominant imaging features were registered. The histopathological diagnosis was considered a reference standard.
RESULTS: Positive predictive power (PPV) for neoplastic lesions was comparable in the Bosniak 3 and 4 categories (75 vs 93.3%, P = .33), while PPV for histopathologically malignant lesion was considerably higher in the latter group (25 vs 93.33%, P = .0002). None of the lesions which had vividly enhancing thin septa as their dominant CEUS feature were malignant. Oncocytoma, multilocular cystic renal neoplasm of low malignant potential, and cystic nephroma were the major benign entities among Bosniak 3 lesions. Localized cystic kidney disease and hemorrhagic cysts were found to be the primary mimickers leading to false positive imaging findings.
CONCLUSIONS: CEUS has a high predictive power for malignancy in the Bosniak 4 category, which is not maintained in the Bosniak 3 group due to the large proportion of benign lesions. Adherence to rigorous rule-in criteria and active surveillance strategies need to be considered for equivocal CEUS Bosniak 3 lesions.
PROBLEM TO BE SOLVED: To provide a warming effect not only in a local point but also in a relatively wide range round it by warming a local part of the body at a temperature higher than a hot water temperature of a specified temperature in the state where a part of the body or the whole body is dipped in the hot water of a prescribed temperature. SOLUTION: In the state where at least a part of the body including a part to be warmed is dipped in a hot water filled in, for example, a bathtub, bucket, or tub, the whole forearm part, for example, is dipped in the hot water within the tub in a warming treatment of forearm local point. The temperature of the hot water is generally set to a bathing temperature of 33-45 deg.C. In the state where the whole forearm part is dipped in the hot water of 33-45 deg.C, a local point of the forearm part is warmed at a temperature higher than this temperature of 37-55 deg.C, preferably, a temperature higher by 1 deg.C. In the warming treatment, a heating element of 37-55 deg.C higher than the temperature of the hot water, for example, is applied, stuck, pressed or adhered to the local, point of the body. More easily, a disposable pocket body warmer 1 can be put in a vessel 2 covered with a waterproof sheet and locally adhered by an adhesive 4 after the mouth is fixed by a chuck 3.
The invention relates to the field of medicine, in particular to polypeptide compounds used for preventing or treating cerebral infarction. Transforming growth factor beta 1 agonist polypeptide 1 is characterized in that the sequence of the transforming growth factor beta 1 agonist polypeptide 1 is HANFCLGPCPY1WSLDTQYS. The transforming growth factor beta 1 agonist polypeptide 1 is prepared by aid of the Fmoc protective solid-phase synthesis technology with Rink amido MBHA resin as the carrier, N,N-DIPCDI as the condensation agent and the trifluoroacetic acid as the cutting reagent. The transforming growth factor beta 1 agonist polypeptide can be in covalent linkage with an adjuvant which is bovine serum albumin, human serum albumin or polyethylene glycol. The invention further relates to the application of the transforming growth factor beta 1 agonist polypeptide in cerebral infarction treatment. The transforming growth factor beta 1 agonist polypeptide can be used to prevent or treat cerebral infarction through various administration methods including subcutaneous injection or intramuscular injection, intravenous injection or intravenous drip, or oral administration such as pills, capsules and nasal sprays. The transforming growth factor beta 1 agonist polypeptide can target to promote expression of the transforming growth factor beta 1, improve the content of the transforming growth factor beta 1 in plasma and achieve the effect of preventing or treating cerebral infarction.
Disclosed and claimed are compositions and methods for therapy and/or prevention of restenosis and/or atherosclerosis. The compositions can include an agent for decreasing viral load of cytomegalovirus, such as an immunological composition or vaccine against cytomegalovirus (CMV) containing at least one epitope of interest of CMV and/or an expression system which expresses at least one epitope of interest of CMV. Such compositions can include at least one epitope of p53. Alternatively, the compositions can include at least one epitope of p53 and/or an expression system which expresses the epitope. The methods can include administering the compositions to a patient in need of such therapy and/or prevention. Additionally, compositions and methods for diagnosing atherosclerosis and/or restenosis, or susceptibility thereto, including screening a sample from a patient for antibodies to CMV and/or CMV proteins and/or screening a sample from a patient for specific viral proteins that predict whether the virus has been reactivated and/or antibodies thereto and/or detecting whether CMV nucleic acid, e.g., mRNA is present in peripheral blood monocytes (PBMCs) and/or detecting a cellular-mediated immune response to CMV peptides or proteins is present and/or HLA phenotyping and/or HLA genotyping. Embodiements can include a skin test.
Cilostazol affects both vascular beds and cardiovascular function. It produces non-homogeneous dilation of vascular beds, with greater dilation in femoral beds than in vertebral, carotid or superior mesenteric arteries. Renal arteries were not responsive to the effects of cilostazol.

In dogs or cynomolgous monkeys, cilostazol increased heart rate, myocardial contractile force, and coronary blood flow as well as ventricular automaticity, as would be expected for a PDE III inhibitor. Left ventricular contractility was increased at doses required to inhibit platelet aggregation. A-V conduction was accelerated. In humans, heart rate increased in a dose-proportional manner by a mean of 5.1 and 7.4 beats per minute in patients treated with 50 and 100 mg b.i.d., respectively. In 264 patients evaluated with Holter monitors, numerically more cilostazol-treated patients had increases in ventricular premature beats and non-sustained ventricular tachycardia events than did placebo-treated; the increases were not dose-related.
In women allocated to groups of cord blood spontaneous drainage, two clamps will placed at 4 finger breadths from the infant's abdomen and cut between two clamps immediately after delivery of the baby. The clamp on the placental site will be removed and the drainage time and amount of cord blood to a measuring glass will be recorded.
Omeprazole delayed-release capsules should be taken before eating. Patients should be informed that the omeprazole delayed-release capsules should be swallowed whole. 

For patients who have difficulty swallowing capsules, the contents of an omeprazole delayed-release capsule can be added to applesauce. One tablespoon of applesauce should be added to an empty bowl and the capsule should be opened. All of the pellets inside the capsule should be carefully emptied on the applesauce. The pellets should be mixed with the applesauce and then swallowed immediately with a glass of cool water to ensure complete swallowing of the pellets. The applesauce used should not be hot and should be soft enough to be swallowed without chewing. The pellets should not be chewed or crushed. The pellets/applesauce mixture should not be stored for future use. 

Advise patients to immediately report and seek care for any cardiovascular or neurological symptoms including palpitations, dizziness, seizures, and tetany as these may be signs of hypomagnesemia [see Warnings and Precautions (5.7)]
The annual number of cases of clinical malaria worldwide is estimated to be 300-500 million leading to 1.5 million deaths. Delayed care and frequent drug resistance of Plasmodium falciparum (Pf), the most frequent form of malaria, is responsible for these deaths. Each year, 5000-8000 travellers return to France with malaria, 4/5 from Africa and with Pf. Clinical features associated with a malaria crisis are poorly predictive and misdiagnosis can be easily made. Diagnosis of accurate malaria rely on microscopic examination of stained thin and thick blood films by a well trained microscopist. Few emergency wards are specialized for tropical diseases. For most of them, malaria is a rare disease and hours are lost before accurate microscopy can permit the decision The rapid diagnostic tests (RDT) for malaria are designed to give a sensitive response within 15 minutes. They are based on the immunodetection of HISTIDIN rich protein 2 (HRP2) or the Pf LACTICO dehydrogenase (PfLDH), specific of Plasmodium falciparum or plasmodial LACTICO dehydrogenase (pLDH), or aldolase, specific of gender of the four species of human malaria. Recent increase of performances and availability prompted WHO to recommend their use for the diagnosis of malaria when microscopy is unavailable. In France, competence exists on the whole of the territory but expertise is usually confined to major referral centers. We intend to evaluate the performances of 4 RDT in 6 laboratories who perform the diagnosis of malaria on patients samples who returned from tourist or family or professional trips. The simultaneous detection of the plasmodial HRP2, PfLDH, aldolase and pLDH will be compared with the thick blood film as reference. Discrepant results will be analysed by PCR. The determination of the sensitivity, the specificity, the predictive positive value and the predictive negative value of the RDT is the principal objective.
The present invention relates to the field of biotechnology. Disclosed are a bifunctional fusion protein, a method for preparing same, and use thereof. The bifunctional fusion protein comprises a VEGF antagonist fragment and a TGF-β antagonist fragment. The VEGF antagonist fragment comprises SEQ ID NOs. 1 and 2 or a polypeptide fragment having 90% or greater sequence identity thereto, and the TGF-β antagonist fragment comprises SEQ ID NO. 3 or a polypeptide fragment having 90% or greater sequence identity thereto. The present invention further provides a method for preparing the bifunctional protein and use of the bifunctional protein in preparing a medicament for treating a disease associated with VEGF and/or TGF-β expression. The bifunctional protein of the present invention is less susceptible to fragmentation in a purification process, and features greatly improved purification efficiency, reduced production cost, and good stability in efficacy and pharmaceutics, thus being prospective in a variety of applications.
The invention discloses an application of CSN6 in colorectal cancer diagnosis and prognosis. The invention identifies the binding protein FASN of CSN6 by protein co-precipitation combined mass spectrometry. Western immunoblotting, protein ubiquitination and protein stability experiments were used to detect post-transcriptional level regulation of downstream proteins by CSN 6. The effect of CSN6 on fatty acid synthesis was observed by lipometabonomics. Tumor cell line growth experiments and metastasis experiments were used to examine the effect of CSN 6-lipid metabolism axis on tumor growth in vitro. Further, by establishing a cell transplantation tumor mouse model, a human tumor tissue source transplantation tumor model and an organoid culture model, the influence of the CSN 6-lipid metabolism axis on tumor growth in vivo is observed. In addition, we used colorectal patient clinical specimens for tissue chip analysis to observe the clinical significance of CSN6 and its related proteins.
###  Teratogenic Effects

Norpace was associated with decreased numbers of implantation sites and decreased growth and survival of pups when administered to pregnant rats at 250 mg/kg/day (20 or more times the usual daily human dose of 12 mg/kg, assuming a patient weight of at least 50 kg), a level at which weight gain and food consumption of dams were also reduced. Increased resorption rates were reported in rabbits at 60 mg/kg/day (5 or more times the usual daily human dose). Effects on implantation, pup growth, and survival were not evaluated in rabbits. There are no adequate and well-controlled studies in pregnant women. Norpace or Norpace CR should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nonteratogenic Effects: Norpace has been reported to stimulate contractions of the pregnant uterus. Disopyramide has been found in human fetal blood.
The primary and secondary outcome of this study was new root caries and arrested root caries. A root surface with new caries experience was recorded when a root surface which was sound at baseline was found to have a carious lesion or a filling at a follow-up examination. Arrested root caries was recorded when the active root caries found at baseline changed into inactive root caries at follow-up. The status of each root surface was recorded using the codes recommended by the International Caries Detection and Assessment System (ICDAS Ⅱ) Coordinating Committee in 2009.

A mean root caries increment of around 0.8 root surface per year of control group was reported in a previous clinical trial conducted in Hong Kong. Thus, in this study, a 24-month increment of 1.6 new decayed root surfaces and a standard deviation of 2 was anticipated. In order to show that a 50% difference in mean caries increment between the test and control groups was statistically significant using a 2-sample t-test at a 5% significance level and at an 80% power, a sample size of 100 subjects in each group was required. Allowing for a drop-out rate of 20% over 24 months, a total of 480 subjects (120 in each group each site) were needed.
Access to mobile applications will be provided for 8 weeks, including the Roy adaptation model-based training and PMR exercises, which include video and training presentations prepared by the consultant and researcher, as a power point presentation. PMR exercises will be uploaded to the system by uploading a follow-up schedule to the system, and it will be ensured that the person can follow himself / herself at least 3 times a week (24 sessions in total) and the researchers can follow the participants.
The invention relates to polymer fibers with microbicidal properties, comprising at least one polymer that can be electrospun and honey and to a method for producing said fibers. The use of honey allows polymers that can be electrospun to be provided with a microbicidal, especially antibacterial finish. The honey as such can be admixed to the solution of the at least one polymer that is to be electrospun, and/or the honey can be incorporated into the polymer fibers in encapsulated form via electrospinning, e.g. in the form of microcapsules. The fibers so obtained can optionally be coated with at least one additional layer of at least one polymer. The polymer fibers that can be obtained by the method according to the invention can be used for textile fibers, for example for producing fibers for activity clothing, protective clothing for medical staff and protective clothing for patients, for medical drapes and dressings or for cosmetic cleaning and care wipes and pads.
PURPOSE:To obtain new antibiotic substance AB4015-B and AB4015-L having antibacterial activity and plant blight pathogen controlling activity and useful as an antibacterial agent, fungicide for agricultural and horticultural use, etc., by culturing a microorganism which belongs to the genus Phoma, capable of producing antibiotic substance AB4015-B in a medium and separating the substance from the cultured product. CONSTITUTION:A microorganism which belongs to the genus Phoma, capable of producing antibiotic substance AB4015-B [e.g. Phoma sp. AB4015 (FERM P-13206)] is inoculated to a medium and cultured at 25 deg.C under shaking for 5 days using a rotary shaker. The microbial cells are collected by filtering the culture liquid, extracted by adding methanol and filtered to obtain a cell extract liquid. The extract is mixed with water and chloroform and extracted by thoroughly shaking the mixture. The chloroform layer is collected and concentrated under reduced pressure and the concentrate is purified by chromatography to obtain the new antibiotic substance expressed by the formula I (R<1> is group of the formula II and R<2> is group of the formula III for AB4015-B; R<1> is group of the formula IV and R<2> is group of the formula V for AB4015-L).
A computer-implemented method (640) and system (100) for sharing patient healthcare information among providers of health services to a patient includes a database (104) configured to contain patient records. The records include an electronic health record (EHR) (606) of the patient, associated with one or more EHR subrecords (608). The database is also configured to contain a plurality of health service provider records (626), and at least one health service network (624) associated with the patient EHR. The network comprises records of one or more health service providers. Each EHR subrecord is associated with an access control structure (630) defining access permissions granted to health service providers in the health service network. In a method according to the invention, a request for access to an EHR subrecord of the patient is received (642), and a health service provider record corresponding with a source of the request for access is identified (644). The access control structure associated with the EHR subrecord is interrogated (648) to determine an access permission of the health service provider associated with the identified health service provider record. Access to the requested EHR subrecord is provided (654) in the event that a required access permission is granted.
Intervention incorporating cognitive factors and focusing on self-initiated movement toward achievement of skill in sitting and reaching to increase problem-solving skills, which will then improve overall developmental outcomes. Visits to home by physical therapist twice weekly with parent training, for 3 months.
INTRODUCTION: Our objective was to conduct an individual patient data meta-analysis (IPDMA) of the two published randomized placebo-controlled trials of mirabegron in people with neurogenic lower urinary tract dysfunction (NLUTD) due to spinal cord injury (SCI) or multiple sclerosis (MS).
METHODS: We identified two randomized, placebo-controlled trials. We extracted individual patient data from the trials and evaluated two primary outcomes: change in maximum cystometric capacity and change in the patient perception of bladder condition (PPBC). We also evaluated several secondary outcomes related to urodynamic function and quality of life. We conducted three exploratory analyses to test hypotheses based on our clinical experiences with mirabegron in NLUTD. Analysis of covariance with adjustment for baseline values was used for the statistical analysis.
RESULTS: Our IPDMA included 98 patients from the two trials. The results showed that mirabegron was associated with a significant improvement in maximum cystometric capacity (+41 mL, p = 0.04) and in the PPBC (-0.8, p < 0.01) compared to placebo. Secondary outcomes including peak neurogenic detrusor overactivity pressure (-20 cm H2O, p < 0.01), incontinence-QOL score (+12, p < 0.01), and 24 h pad weights (-79 g, p = 0.04) also improved significantly compared to placebo. Exploratory analyses found similar improvements in people with MS and SCI; some outcomes improved to a greater degree among people with incomplete SCI, or SCIs that were below T7.
CONCLUSIONS: Our IPDMA provides evidence supporting the use of mirabegron in patients with NLUTD due to SCI or MS. Further work evaluating differential responses in people with different SCI lesion characteristics may be warranted.